We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Nevro shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 43.8% gain over the past four weeks.
The recent surge in Nevro shares can be attributed to the announcement of Globus Medical acquiring Nevro in an-all cash transaction for a valuation of approximately $250 million. The transaction is expected to close late in the second quarter of 2025. This acquisition can be highly beneficial for NVRO as it combines its expertise in innovative pain management solutions with Globus Medical’s broader resources and technological capabilities. This synergy may accelerate product development, expand market reach, and provide patients with more comprehensive treatment options.
This maker of an electrical implant that treats leg and back pain is expected to post quarterly loss of $0.79 per share in its upcoming report, which represents a year-over-year change of -426.7%. Revenues are expected to be $105.65 million, down 9.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nevro, the consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NVRO going forward to see if this recent jump can turn into more strength down the road.
Nevro is part of the Zacks Medical - Instruments industry. OrthoPediatrics (KIDS - Free Report) , another stock in the same industry, closed the last trading session 3.9% lower at $23.71. KIDS has returned 2% in the past month.
OrthoPediatrics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.22. Compared to the company's year-ago EPS, this represents a change of +4.4%. OrthoPediatrics currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 43.8% gain over the past four weeks.
The recent surge in Nevro shares can be attributed to the announcement of Globus Medical acquiring Nevro in an-all cash transaction for a valuation of approximately $250 million. The transaction is expected to close late in the second quarter of 2025. This acquisition can be highly beneficial for NVRO as it combines its expertise in innovative pain management solutions with Globus Medical’s broader resources and technological capabilities. This synergy may accelerate product development, expand market reach, and provide patients with more comprehensive treatment options.
This maker of an electrical implant that treats leg and back pain is expected to post quarterly loss of $0.79 per share in its upcoming report, which represents a year-over-year change of -426.7%. Revenues are expected to be $105.65 million, down 9.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Nevro, the consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NVRO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Nevro is part of the Zacks Medical - Instruments industry. OrthoPediatrics (KIDS - Free Report) , another stock in the same industry, closed the last trading session 3.9% lower at $23.71. KIDS has returned 2% in the past month.
OrthoPediatrics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.22. Compared to the company's year-ago EPS, this represents a change of +4.4%. OrthoPediatrics currently boasts a Zacks Rank of #3 (Hold).